Indomethacin (Synonyms: 吲哚美辛; Indometacin)

目录号: HY-14397 纯度: 99.91%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Indomethacin (Indometacin) 是一种有效的口服活性 COX1/2 抑制剂，COX-1 和 COX-2 的IC₅₀ 值分别为 18 nM 和 26 nM。Indomethacin 具有抗癌和抗感染活性。Indomethacin 可用于癌症、炎症和病毒感染的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Indomethacin Chemical Structure

CAS No. : 53-86-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
100 mg	￥140	In-stock
500 mg	￥350	In-stock
1 g	￥450	In-stock
5 g	￥800	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Indomethacin:

MCE 顾客使用本产品发表的 40 篇科研文献

Indomethacin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看所有亚型

COX COX-1 COX-2 COX-3

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
纯度 & 产品资料
参考文献

生物活性

Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC₅₀ values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research^[1]^[2]^[3].

IC₅₀ & Target^[1]

Human COX-1

18 nM (IC₅₀, in CHO cells)

Human COX-2

26 nM (IC₅₀, in CHO cells)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
2008	IC₅₀	12.6 μM Compound: indometacin	Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay	[PMID: 21354800]
A549	IC₅₀	> 100 μM Compound: Indomethacin	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 20583750]
A549	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
A549	IC₅₀	40.6 μM Compound: indomethacin	Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as inhibition of PGE2 formation from PGH2 after 15 mins by RP-HPLC analysis	[PMID: 22992107]
Bel-7402	IC₅₀	> 100 μM Compound: Indomethacin	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
Bel7402/5-FU	IC₅₀	> 100 μM Compound: Indomethacin	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
BJ	IC₅₀	> 50 μM Compound: C	Cytotoxicity against human BJ cells after 72 hrs by luminescence assay Cytotoxicity against human BJ cells after 72 hrs by luminescence assay	[PMID: 20129783]
BV-2	IC₅₀	34.5 μM Compound: Indomethacin	Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 10 mins followed by LPS stimulation for 24 hrs by Griess assay	[PMID: 27120704]
BV-2	IC₅₀	35.7 μM Compound: indomethacin	Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay Inhibition of LPS-activated nitric oxide production in mouse BV2 cells pre-treated for 60 mins before LPS challenge for 24 hrs by Griess assay	[PMID: 26348503]
BV-2	IC₅₀	7.1 μM Compound: Indomethacin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 24042007]
CHO	IC₅₀	0.026 μM Compound: Indomethacin	In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2 In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 2	[PMID: 9873621]
CHO	IC₅₀	0.049 μM Compound: Indomethacin	Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2 Inhibition of PGE-2 production by arachidonic acid-stimulated CHO cells expressing human Prostaglandin G/H synthase 2	10.1016/S0960-894X(96)00501-X
CHO	IC₅₀	25 μM Compound: 5	Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA	[PMID: 20503989]
CHO	IC₅₀	25 μM Compound: 2	Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA	[PMID: 21873070]
COS-7	IC₅₀	> 1000 μM Compound: Indomethacin	Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
CV-1	EC₅₀	50 μM Compound: Indomethacin	Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay Activation of GAL4 fused human PPARgamma ligand binding domain transfected in african green monkey CV1 cells by CAT reporter assay	[PMID: 16643023]
DU-145	IC₅₀	> 100 μM Compound: 4; Ind	Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human DU-145 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
Erythrocyte	IC₅₀	0.086 μg/mL Compound: Indomethacin	Hemolytic activity in human RBC assessed as membrane mortification by absorbance method Hemolytic activity in human RBC assessed as membrane mortification by absorbance method	[PMID: 29803359]
Erythrocyte	IC₅₀	40 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method	[PMID: 30108882]
Erythrocyte	IC₅₀	40.04 μg/mL Compound: Indomethacin	Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method Anti-inflammatory activity in human RBC assessed as inhibition of hypotonic solution-induced hemolysis after 10 mins by spectrophotometric method	[PMID: 30108827]
HCT-116	IC₅₀	136.8 μM Compound: INDO	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
HCT-15	IC₅₀	> 1000 μM Compound: Indomethacin	Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HEK293	IC₅₀	> 50 μM Compound: C	Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay	[PMID: 20129783]
HEK293	IC₅₀	> 500 μM Compound: indomethacin	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	[PMID: 23241029]
HEK293	IC₅₀	12 μM Compound: Indometacin	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	140 μM Compound: Indometacin	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	41 μM Compound: Indometacin	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HeLa	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
HeLa	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
HeLa	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
HeLa	EC₅₀	0.14 nM Compound: 1, IMN	Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay Agonist activity at androgen receptor (unknown origin) expressed in HeLa cells co-expressing PSA-(ARE)4-Luc13 assessed as induction of DHT-induced luciferase activity after 20 mins by luciferase reporter gene assay	[PMID: 23432095]
HeLa	IC₅₀	50 μM Compound: Indomethacin	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20583750]
HepG2	IC₅₀	> 50 μM Compound: C	Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay	[PMID: 20129783]
HT-29	IC₅₀	> 100 μM Compound: 4; Ind	Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
HT-29	IC₅₀	1052 μM Compound: Indomethacin	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22940705]
HT-29	IC₅₀	312.6 μM Compound: INDO	Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HT-29 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
J774	IC₅₀	> 100 μM Compound: Indomethacin	Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay Cytotoxicity against mouse J774 cells assessed as cell survival after 24 hrs by MTT assay	[PMID: 24268542]
J774	IC₅₀	29.6 μM Compound: Indomethacin	Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse J774 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 24268542]
J774.A1	IC₅₀	28.42 μM Compound: Indomethacin	Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent Antiinflammatory activity in mouse J774A1 cells assessed as reduction of LPS-induced nitric oxide production treated 2 hrs before LPS addition measured after 20 hrs by using Griess reagent	[PMID: 23688954]
J774.A1	IC₅₀	28.56 μM Compound: Indomethacin	Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs Antiinflammatory activity in mouse J774.A1 cells assessed as inhibition of LPS-induced NO production treated 2 hrs before LPS challenge measured after 20 hrs	[PMID: 25140384]
K562	IC₅₀	190 μM Compound: Indomethacin	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
L02	IC₅₀	> 100 μM Compound: Indomethacin	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
LNCaP	IC₅₀	> 300 μM Compound: Indomethacin	Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 28057407]
LNCaP	IC₅₀	238.4 μM Compound: INDO	Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human LNCAP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
Macrophage	IC₅₀	22 μM Compound: indomethacin	Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced PGE2 release by Ellman's method	[PMID: 8988605]
MCF7	IC₅₀	> 100 μM Compound: 4; Ind	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 36257283]
MCF7	IC₅₀	> 100 μM Compound: Indomethacin	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20583750]
MCF7	IC₅₀	> 1000 μM Compound: Indomethacin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
MCF7	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
MCF7	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
MCF7	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
MDA-MB-231	IC₅₀	> 100 μM Compound: Indomethacin	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20583750]
Neutrophil	IC₅₀	271.212 μM Compound: Indomethacin	Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay Antiinflammatory activity in human neutrophils assessed as inhibition of opsonized zymosan A-mediated superoxide anions production by WST-1 based respiratory burst assay	[PMID: 22437110]
Neutrophil	IC₅₀	38.3 μM Compound: Indomethacin	Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry Antiinflammatory activity against human neutrophil assessed as inhibition of N-formyl-l-methionyl phenylalanine/cytochalasin B-induced superoxide anion generation by spectrophotometry	[PMID: 21316977]
PC-3	IC₅₀	> 100 μM Compound: Indomethacin	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 20583750]
PC-3	IC₅₀	> 1000 μM Compound: Indomethacin	Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
Platelet	IC₅₀	0.1 μM Compound: Indomethacin	Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	0.21 μM Compound: Indomethacin	Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich blood by turbidimetric method	[PMID: 8988600]
Platelet	IC₅₀	1.62 μM Compound: Indomethacin	Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 3 mins before arachidonic acid challenge by turbidimetric method	[PMID: 23639653]
Platelet	IC₅₀	2.8 μM Compound: Indomethacin	Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Platelet	IC₅₀	3.2 μM Compound: Indomethacin	Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins	[PMID: 114655]
Raji	IC₅₀	> 50 μM Compound: C	Cytotoxicity against human Raji cells after 72 hrs by luminescence assay Cytotoxicity against human Raji cells after 72 hrs by luminescence assay	[PMID: 20129783]
RAW	IC₅₀	15.37 μM Compound: indomethacin	Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA Inhibition of COX2-mediated PGE2 production in LPS-stimulated mouse RAW 264.7 cells after 24 hrs by ELISA	[PMID: 21381754]
RAW	IC₅₀	23.47 μM Compound: indomethacin	Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells treated 2 hrs before LPS challenge measured after 18 hrs by Griess reaction method	[PMID: 21381754]
RAW	IC₅₀	48.89 μM Compound: indomethacin	Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis Inhibition of iNOS in LPS-stimulated mouse RAW 264.7 cells after 2 hrs by fluorescence plate reader analysis	[PMID: 21381754]
RAW264.7	IC₅₀	> 10 μM Compound: Ind	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay	[PMID: 32823004]
RAW264.7	IC₅₀	> 100 μM Compound: indomethacin	Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 21381754]
RAW264.7	IC₅₀	> 100 μM Compound: indomethacin	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 21381754]
RAW264.7	CC₅₀	> 200 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27575472]
RAW264.7	IC₅₀	> 40 μM Compound: Ind	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in presence of LPS by MTT assay	[PMID: 32823004]
RAW264.7	IC₅₀	> 40 μM Compound: Ind	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability incubated for 24 hrs in absence of LPS by MTT assay	[PMID: 32823004]
RAW264.7	CC₅₀	> 50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability by MTT assay	[PMID: 31365251]
RAW264.7	IC₅₀	> 50 μM Compound: Indomethacin	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 30920218]
RAW264.7	IC₅₀	> 80 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 25555141]
RAW264.7	IC₅₀	> 80 μM Compound: Indo	Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay Cytotoxicity against LPS-stimulated mouse RAW264.7 cells after 24 hrs by MTT assay	[PMID: 25555141]
RAW264.7	IC₅₀	> 80 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the absence of LPS	[PMID: 22633833]
RAW264.7	IC₅₀	> 80 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS Cytotoxicity against mouse RAW264.7 cells after 24 hrs by MTT assay in the presence of LPS	[PMID: 22633833]
RAW264.7	IC₅₀	0.62 μM Compound: Ind	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production preincubated for 3 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 36888988]
RAW264.7	IC₅₀	1.25 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 24806310]
RAW264.7	IC₅₀	10.7 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in absence of LPS by MTT assay	[PMID: 25881822]
RAW264.7	IC₅₀	10.99 μM Compound: Indometacin	Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay Antiinflammatory activity against LPS-induced mouse RAW264.7 cells assessed as inhibition of NO production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by Greiss reagent based assay	[PMID: 34352712]
RAW264.7	IC₅₀	11.6 μM Compound: Indomethacin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay	[PMID: 27276091]
RAW264.7	IC₅₀	12.1 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 23755850]
RAW264.7	IC₅₀	12.5 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 26702644]
RAW264.7	IC₅₀	12.96 μM Compound: indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by MTT assay	[PMID: 20879743]
RAW264.7	IC₅₀	12.96 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess reaction based spectrophotometry	[PMID: 21807513]
RAW264.7	IC₅₀	13.2 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production after 24 hrs in presence of LPS by colorimetric analysis	[PMID: 27865705]
RAW264.7	IC₅₀	14.1 μM Compound: indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 1 day by Griess assay	[PMID: 25821895]
RAW264.7	IC₅₀	148 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 23566521]
RAW264.7	IC₅₀	15.8 μM Compound: Indomethacin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay	[PMID: 24963714]
RAW264.7	IC₅₀	16.5 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reagent based assay	[PMID: 27575472]
RAW264.7	IC₅₀	16.67 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 26615888]
RAW264.7	IC₅₀	16.67 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 24660966]
RAW264.7	IC₅₀	16.7 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs by Griess reagent based assay	[PMID: 33533247]
RAW264.7	IC₅₀	18.7 μM Compound: Indomethacin	Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA	[PMID: 24963714]
RAW264.7	IC₅₀	20 μM Compound: Indo	Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay Inhibition of iNOS in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production for 2 hrs by DAF-FMDA dye based fluorometric assay	[PMID: 22633833]
RAW264.7	IC₅₀	21.1 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 1 hr followed by LPS stimulation measured after 24 hrs by griess assay	[PMID: 29261312]
RAW264.7	IC₅₀	24 μM Compound: Indomethacin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation measured after 48 hrs by MTT assay	[PMID: 33160760]
RAW264.7	IC₅₀	26.2 μg/mL Compound: Indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of IFN-gamma and LPS-induced COX2 production preincubated for 2 hrs followed by IFN-gamma and LPS stimulation and measured after 16 hrs by spectrophotometric analysis	[PMID: 33422907]
RAW264.7	IC₅₀	32.2 μM Compound: Indomethacin	Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay Inhibition of LPS-stimulated nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent-based assay	[PMID: 32247751]
RAW264.7	IC₅₀	32.3 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production for 24 hrs by Griess assay	[PMID: 33422907]
RAW264.7	IC₅₀	33.6 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay	[PMID: 28960979]
RAW264.7	IC₅₀	33.6 μM Compound: Indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 30024153]
RAW264.7	IC₅₀	34.28 μM Compound: Indomethacin	Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay Inhibition of LPS induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent based assay	[PMID: 35660249]
RAW264.7	IC₅₀	38 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs coincubated with LPS by Griess reagent based assay	[PMID: 31365251]
RAW264.7	IC₅₀	4.5 μM Compound: Indo	Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells using L-Arginine substrate incubated for 2 hrs by fluorescence spectrometry	[PMID: 25881822]
RAW264.7	IC₅₀	40.3 μM Compound: Indo	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 2 hrs before LPS challenge measured 18 hrs post LPS challenge by Griess method	[PMID: 25555141]
RAW264.7	IC₅₀	40.7 μM Compound: INDO	Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay	[PMID: 35175765]
RAW264.7	IC₅₀	41 μM Compound: Indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production measured after 24 hrs	[PMID: 30920218]
RAW264.7	IC₅₀	42.2 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation measured after 20 hrs by Griess assay	[PMID: 26710212]
RAW264.7	IC₅₀	42.3 μM Compound: Indometacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS stimulation and measured after 36 hrs by Griess reagent based assay	[PMID: 35512012]
RAW264.7	IC₅₀	42.6 μM Compound: Indomethacin	Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay Anti-inflammatory activity in mouse RAW264.7 cells assessed as LPS-stimulated inhibition of nitric oxide production incubated simultaneously with LPS for 24 hrs by Griess reagent based assay	[PMID: 26024020]
RAW264.7	IC₅₀	42.6 μM Compound: indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 25945867]
RAW264.7	IC₅₀	45.51 μM Compound: Indo	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess reagent method	[PMID: 19931461]
RAW264.7	IC₅₀	45.57 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hr followed by LPS addition and measured after 24 hrs by Griess reagent-based assay	[PMID: 30925056]
RAW264.7	IC₅₀	46.5 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
RAW264.7	IC₅₀	52.8 nM Compound: Indomethacin	Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs by Griess reagent method	[PMID: 19467877]
RAW264.7	IC₅₀	6.3 μM Compound: indomethacin	Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced NO production after 24 hrs	[PMID: 25621853]
RAW264.7	IC₅₀	62.9 μM Compound: Indomethacin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells incubated for 24 hrs by Griess reagent based assay	[PMID: 31403786]
RAW264.7	IC₅₀	8.8 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production measured after 18 hrs by Griess assay	[PMID: 32520548]
RAW264.7	IC₅₀	8.8 μM Compound: Indomethacin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs followed by LPS challenge and measured after 12 hrs by Griess assay	[PMID: 31573805]
RAW264.7	IC₅₀	9.2 μM Compound: Indo	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs in presence of LPS by MTT assay	[PMID: 25881822]
Sf9	IC₅₀	0.75 μM Compound: 1, Indomethacin	Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis Inhibition of human COX2 expressed in SF-9 insect cells assessed as conversion of [14C]-arachidonic acid to [14C]-prostaglandins preincubated for 20 mins by thin-layer chromatography analysis	[PMID: 21524587]
SK-LU-1	IC₅₀	> 1000 μM Compound: Indomethacin	Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
SW480	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32987314]
SW480	IC₅₀	> 50 μM Compound: Indometacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32987314]
TERT-RPE1	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
THP-1	IC₅₀	> 10 μM Compound: indomethacin	Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4 Effect of pyrrolidine derivatives on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4	[PMID: 10737736]
THP-1	IC₅₀	> 10 μM Compound: indomethacin	Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay Inhibition of arachidonic acid production from THP-1 cells stimulated with A-23187 using cellular assay	[PMID: 10737736]
THP-1	IC₅₀	0.0036 μM Compound: indomethacin	Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4 Effect on production of eicosanoids from THP-1 cells stimulated with A-23187 using cellular assay on PGE-2, LTC-4	[PMID: 10737736]
U-251	IC₅₀	20.45 μM Compound: Indomethacin	Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
U-937	IC₅₀	0.02 μM Compound: Indomethacin	Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells incubated in low concentration of arachidonic acid	[PMID: 9873621]
VCaP	IC₅₀	136.9 μM Compound: INDO	Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human VCaP cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 30996776]
Vero C1008	CC₅₀	> 100 μM Compound: 1; INM	Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells infected with SARS-CoV-2 assessed as reduction of cell viability measured after 48 hrs by MTT assay	[PMID: 34534839]
Vero C1008	CC₅₀	> 500 μM Compound: 1; INM	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay	[PMID: 34534839]

体外研究
(In Vitro)

Indomethacin (Indometacin) (0-150 μM; 24 hours; 3LL-D122 cells) has anticancer activity in vitro^[2].
Indomethacin (Indometacin) (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in elF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC₅₀=2μM)^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells)
Concentration:	0, 20, 50, 100 and 150μM
Incubation Time:	24 hours
Result:	Inhibited cell viability at 20 mM, with 50% inhibition at 60 mM.

Cell Viability Assay^[2]

Cell Line:	3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells)
Concentration:	0, 30 and 80μM
Incubation Time:	24 hours
Result:	Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase.

体内研究
(In Vivo)

Indomethacin 可用于诱导胃溃疡模型。口服后，药物吸收迅速且完全，尽管存在个体间和个体内差异。通常情况下，血浆峰值浓度 (2-3 μg/mL) 在 1-2 小时内达到。然而，与食物同服会降低并延迟峰值浓度的出现，但不影响总吸收量。在治疗浓度下，90% 的 Indomethacin 与血浆中的白蛋白结合^[4]。

诱导胃溃疡^[5]^[6]

致病原理

Indomethacin 可通过多种机制引起胃溃疡，包括通过抑制前列腺素（PG）合成、减少局部血流量、局部刺激和抑制组织再生而造成的损伤。

具体造模方法：

大鼠：白化病大鼠 • Sprague-Dawley • 雄性 • adult (处理：2 周)
给药方式：100 mg/kg • 口服 • 单剂量

Note

(1) 所有动物给药前24 h 禁食。
(2) Indomethacin 溶解于含 5% NaOH 的生理盐水中。

造模成功指标

胃组织宏观改变：胃粘膜皱襞明显，糜烂严重，溃疡、出血灶明显。
组织病理学变化：粘膜严重糜烂，向下到达肌层；可见出血浸润、粘膜下层水肿、血管严重充血。
分子变化：显示出强烈的Tnf-α表达。
生化变化：MDA、TOS 水平升高，TAS 水平降低，CAT 和 GPx 活性以及 GSH 水平降低。

相关产品： Indomethacin sodium hydrate (HY-14397A)

拮抗产品： Carnosic acid (HY-N0644)

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats^[1]
Dosage:	0.01-10 mg/kg
Administration:	Oral administration; for 3 hours
Result:	Inhibited the carrageenan-induced rat paw oedema (ED₅₀=2.0 mg/kg) and hyperalgesia (ED₅₀=1.5 mg/kg) in a dose-dependent manner.

Animal Model:	Male C57BL/6J mice^[2]
Dosage:	10 mg/mL
Administration:	Oral administration; daily, for 29 days
Result:	Delayed the onset of tumor growth and the initial growth rate of the footpad tumors.

Clinical Trial

分子量

357.79

Formula

C₁₉H₁₆ClNO₄

CAS 号

53-86-1

性状

固体

颜色

White to off-white

中文名称

吲哚美辛

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (279.49 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

Ethanol 中的溶解度 : 12.5 mg/mL (34.94 mM; 超声助溶)

H₂O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7949 mL	13.9747 mL	27.9494 mL
5 mM	0.5590 mL	2.7949 mL	5.5899 mL
10 mM	0.2795 mL	1.3975 mL	2.7949 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.81 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.81 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.81 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案四

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (3.49 mM); 澄清溶液

此方案可获得 ≥ 1.25 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案五

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.49 mM); 澄清溶液

此方案可获得 ≥ 1.25 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案六

请依序添加每种溶剂： 10% EtOH 90% Corn Oil
Solubility: ≥ 1.25 mg/mL (3.49 mM); 澄清溶液

此方案可获得 ≥ 1.25 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 12.5 mg/mL 的澄清 EtOH 储备液加到 900 μL 玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.91%

选择批次：

Data Sheet (671 KB) SDS (479 KB)

COA (291 KB) HNMR (279 KB) RP-HPLC (243 KB) LCMS (93 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Riendeau D, et, al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17. [Content Brief]

[2]. Eli Y, et, al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001 Mar 1;61(5):565-71. [Content Brief]

[3]. Amici C, et, al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell Microbiol. 2015 Sep;17(9):1391-404. [Content Brief]

[4]. Helleberg L, et, al. Clinical Pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981 Jul-Aug;6(4):245-58. [Content Brief]

[5]. Sabiu S, et, al. Indomethacin-induced gastric ulceration in rats: Protective roles of Spondias mombin a nd Ficus exasperate. Toxicol Rep. 2015 Jan 8:2:261-267. [Content Brief]

[6]. Danisman B, et, al, Carnosic Acid Ameliorates Indomethacin-Induced Gastric Ulceration in Rats by Alleviating Oxidative Stress and Inflammation. Biomedicines. 2023 Mar 9;11(3):829. [Content Brief]

Indomethacin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	2.7949 mL	13.9747 mL	27.9494 mL	69.8734 mL
	5 mM	0.5590 mL	2.7949 mL	5.5899 mL	13.9747 mL
	10 mM	0.2795 mL	1.3975 mL	2.7949 mL	6.9873 mL
	15 mM	0.1863 mL	0.9316 mL	1.8633 mL	4.6582 mL
	20 mM	0.1397 mL	0.6987 mL	1.3975 mL	3.4937 mL
	25 mM	0.1118 mL	0.5590 mL	1.1180 mL	2.7949 mL
	30 mM	0.0932 mL	0.4658 mL	0.9316 mL	2.3291 mL
DMSO	40 mM	0.0699 mL	0.3494 mL	0.6987 mL	1.7468 mL
	50 mM	0.0559 mL	0.2795 mL	0.5590 mL	1.3975 mL
	60 mM	0.0466 mL	0.2329 mL	0.4658 mL	1.1646 mL
	80 mM	0.0349 mL	0.1747 mL	0.3494 mL	0.8734 mL
	100 mM	0.0279 mL	0.1397 mL	0.2795 mL	0.6987 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Indomethacin53-86-1Indometacin吲哚美辛COXAntibioticInfluenza VirusBacterialCyclooxygenaseanti-infectiveanticancerinflammationCOX-1COX-2Inhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Indomethacin (Synonyms: 吲哚美辛; Indometacin)

Customer Review

Other Forms of Indomethacin:

MCE 顾客使用本产品发表的 40 篇科研文献

Indomethacin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Indomethacin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Indomethacin (Synonyms: 吲哚美辛; Indometacin)

Customer Review

Other Forms of Indomethacin:

Indomethacin 相关抗体

MCE 顾客使用本产品发表的 40 篇科研文献

Indomethacin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 COX 亚型特异性产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Indomethacin 相关抗体:

摩尔计算器

稀释计算器

Indomethacin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z